BLC
VRTX icon

Brown, Lisle/Cummings’s Vertex Pharmaceuticals VRTX Stock Holding History

Brown, Lisle/Cummings’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1K Hold
115
– – 0.01% 365
2026
Q1 		$51.4K Buy
115
+33
+40% +$15.4K 0.01% 356
2025
Q4 		$37.2K Hold
82
– – 0.01% 369
2025
Q3 		$32.1K Hold
82
– – 0.01% 383
2025
Q2 		$36.5K Hold
82
– – 0.01% 367
2025
Q1 		$39.8K Buy
82
+7
+9% +$3.26K 0.01% 351
2024
Q4 		$30.2K Buy
+75
New +$34.8K 0.01% 370

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brown, Lisle/Cummings's VRTX Position: Q2 2026 in Review

Brown, Lisle/Cummings held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 115 shares worth $57.1K. The position accounts for 0.01% of the portfolio, ranked #365.

Brown, Lisle/Cummings first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Brown, Lisle/Cummings held 115 shares of Vertex Pharmaceuticals worth $57.1K as of Q2 2026.
  • Brown, Lisle/Cummings left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up 0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #365 holding.
  • Brown, Lisle/Cummings first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.